Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against BIOL
Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against BIOLASE, Inc.
WILMINGTON, Del.--(BUSINESS WIRE)-- Rigrodsky & Long, P.A.:
Do you, or did you, own shares of BIOLASE, Inc. (NASDAQ CM:BIOL)?
Did you purchase your shares before January 7, 2013, or between January 7, 2013 and August 12, 2013, inclusive?
Did you lose money in your investment in BIOLASE, Inc.?
Do you want to discuss your rights?
Rigrodsky & Long, P.A., including former Special Assistant United States Attorney, Timothy J. MacFall, announces that a complaint has been filed in the United States District Court for the Central District of California on behalf of all persons or entities that purchased the common stock of BIOLASE, Inc. ("BIOLASE" or the "Company") (NASDAQ CM: BIOL) between January 7, 2013 and August 12, 2013, inclusive (the "Class Period"), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the "Complaint").
If you purchased shares of BIOLASE during the Class Period and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 825 East Gate Boulevard, Suite 300, Garden City, NY at (888) 969-4242, by e-mail to info@rl-legal.com, or at: http://www.rigrodskylong.com/investigations/biolase-inc-biol.
BIOLASE is a biomedical company operating in one reportable business segment that develops, manufactures, and markets proprietary lasers in dentistry and medicine and also markets and distributes two-dimensional ("2-D") and three-dimensional ("3-D") digital imaging equipment and CAD/CAM intra-oral scanners; products that are focused on technologies that advance the practice of dentistry and medicine. The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements, and omitted materially adverse facts, about the Company's business, operations and prospects. Specifically, the Complaint alleges that the defendants concealed from the investing public that: (1) contrary to Defendants' statements during the Class Period that dental lasers were "becom[ing] the standard of care in dental practices worldwide" and feeding demand for BIOLASE's product offerings, in reality, because there is little evidence demonstrating the use of dental lasers (instead of drills) provides long-term benefits to teeth, and because both children and adults can have cavities filled without the numbing injections BIOLASE claims WaterLase products preclude, only 5% of dental offices use dental lasers and dentists were hesitant to adopt dental lasers - especially BIOLASE's - because of their high costs; (2) due to the relatively high costs associated with its dental lasers offerings, BIOLASE's efforts to switch to a direct sales model in the U.S. during the Class Period were failing; (3) contrary to Defendants' Class Period statements that they did "not expect to be troubled with the multitude of extraneous issues that [BIOLASE] faced throughout [its] challenging turnaround, including exiting [its] exclusive global distribution relationship with Henry Schein," the high debt burden the Company assumed to exit the Henry Schein arrangement, coupled with the onerous terms of the Comerica lines of credit, were financially handicapping the Company; and (4) contrary to Defendants' Class Period statements that "the cash generated from operations and the borrowings available under the lines of credit with Comerica Bank [would] be sufficient to fund [BIOLASE's] working capital requirements for 2013," there was no cash being generated from operations and the Company was in default of the Comerica lines of credit. As a result of defendants' false and misleading statements, the Company's stock traded at artificially inflated prices during the Class Period.
According to the Complaint, on August 7, 2013, after the close of trading, the Company issued a press release announcing its second quarter 2013 financial results. Rather than the $15.69 million in revenues Defendants had led the market to expect through their bullish Class Period statements, BIOLASE reported revenues of just $14.2 million - down 2.74% from the $14.6 million the Company had reported in the fourth quarter 2012. Rather than the $0.04 per share loss Defendants had led the market to expect, and had reported in the second quarter of 2012, BIOLASE reported a loss of $0.06 per share.
On this news, shares in BIOLASE dropped more than 26%, closing at $2.51 per share on August 8, 2013, from a close of $3.42 per share on August 7, 2013, on unusually heavy trading volume of over 1.9 million shares.
If you wish to serve as lead plaintiff, you must move the Court no later than October 22, 2013. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
While Rigrodsky & Long, P.A. did not file the Complaint in this matter, the firm, with offices in Wilmington, Delaware and Garden City, New York, regularly litigates securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, including claims for breach of fiduciary duty and proxy violations in the Delaware Court of Chancery and in state and federal courts throughout the United States.
Attorney advertising. Prior results do not guarantee a similar outcome.
Rigrodsky & Long, P.A.
Timothy J. MacFall, Esquire
Peter Allocco
888-969-4242
516-683-3516
Fax: 302-654-7530
info@rl-legal.com
http://www.rigrodskylong.com
KEYWORDS: United States North America Delaware
INDUSTRY KEYWORDS:
The article Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against BIOLASE, Inc. originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
